Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Inhibition of IRF5 hyperactivation protects from lupus onset and severity.
Song S, De S, Nelson V, Chopra S, LaPan M, Kampta K, Sun S, He M, Thompson CD, Li D, Shih T, Tan N, Al-Abed Y, Capitle E, Aranow C, Mackay M, Clapp WL, Barnes BJ. Song S, et al. Among authors: lapan m. J Clin Invest. 2020 Dec 1;130(12):6700-6717. doi: 10.1172/JCI120288. J Clin Invest. 2020. PMID: 32897883 Free PMC article. Clinical Trial.
Inhibition of IRF5 cellular activity with cell-penetrating peptides that target homodimerization.
Banga J, Srinivasan D, Sun CC, Thompson CD, Milletti F, Huang KS, Hamilton S, Song S, Hoffman AF, Qin YG, Matta B, LaPan M, Guo Q, Lu G, Li D, Qian H, Bolin DR, Liang L, Wartchow C, Qiu J, Downing M, Narula S, Fotouhi N, DeMartino JA, Tan SL, Chen G, Barnes BJ. Banga J, et al. Among authors: lapan m. Sci Adv. 2020 May 15;6(20):eaay1057. doi: 10.1126/sciadv.aay1057. eCollection 2020 May. Sci Adv. 2020. PMID: 32440537 Free PMC article.